Search results for " nonavalent vaccine"

showing 2 items of 2 documents

Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations

2021

AbstractHuman papilloma virus infection (HPV) is the most common sexually transmitted disease. Little is known about male infection. Nonavalent vaccine against types 6/11/16/18/31/33/45/52/58 was approved and neutral gender immunization programs have been proposed. This study evaluates the potential impact of nonavalent vaccine compared to quadrivalent in male living in Sicily (Italy). 58.7% of samples were HPV positive and forty-four types of HPV were identified. A significant higher estimated coverage of nonavalent vaccine than quadrivalent was observed (64.3% vs. 45.8%), with absolute and relative additional impact of 20.1% and 47.2%, respectively. Low impact of the vaccine were calculat…

Hpv genotypesSexually transmitted diseaseAdultMalemedicine.medical_specialtyScienceDiseasesMicrobiologyArticle03 medical and health sciencesYoung Adult0302 clinical medicineMedical researchHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Internal medicineMedicineHumansHuman papilloma virus infection030212 general & internal medicinePapillomavirus VaccinesPapillomaviridaeSicilyAgedPotential impactMultidisciplinarybusiness.industryHPV PositivePapillomavirus InfectionsQHealth careRMiddle Aged030220 oncology & carcinogenesisCase-Control StudiesMedicinebusinessSexual contactHPV nonavalent vaccine men infectious desease
researchProduct

Overview of the benefitsand potential issues of the nonavalent HPV vaccine

2017

HPV-related diseases affect anogenital and oropharyngeal regions, heavily affecting the psychosexual dimension of both male and female individuals. HPV vaccination programs based on a bivalent or quadrivalent vaccine have opened broad perspectives for primary prevention. A nonavalent HPV vaccine (9vHPV), covering nine genotypes (HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9vHPV vaccine development programs are examined. Efficacy data come from a pivotal trial, which was conducted among women aged 16–26 years randomly assigned to receive either the 9vHP…

MaleHPVmedicine.medical_specialtyUterine Cervical NeoplasmsDiseaseAnatomic region03 medical and health sciences0302 clinical medicineHPV nonavalent vaccinePrimary preventionEnvironmental healthmedicineHumansPapillomavirus Vaccines030212 general & internal medicineCervical cancer; HPV; HPV nonavalent vaccine; Prevention; Female; Humans; Male; Papillomaviridae; Papillomavirus Infections; Papillomavirus Vaccines; Randomized Controlled Trials as Topic; Uterine Cervical NeoplasmsPapillomaviridaeRandomized Controlled Trials as TopicGynecologyCervical cancerbusiness.industryPreventionPapillomavirus InfectionsObstetrics and GynecologyHpv vaccinationGeneral Medicinemedicine.disease030220 oncology & carcinogenesisCervical cancer; HPV; HPV nonavalent vaccine; PreventionCervical cancerFemalebusiness
researchProduct